Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy

被引:428
作者
Yamagishi, S [1 ]
Imaizumi, T [1 ]
机构
[1] Kurume Univ, Sch Med, Dept Internal Med 3, Kurume, Fukuoka 8300011, Japan
关键词
diabetic vascular complications; atherosclerosis; AGEs; oxidative stress; PKC; polyol pathway; renin-angiotensin system; insulin resistance;
D O I
10.2174/1381612054367300
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Diabetic vascular complication is a leading cause of end-stage renal failure, acquired blindness, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Recent large prospective clinical studies have shown that intensive glucose control reduces effectively microvascular complications among patients with diabetes. and insulin resistance and postprandial hyperglycemia seem to be involved in diabetic macrovascular complications. Chronic hyperglycemia is a major initiator of diabetic vascular complications. Indeed. high glucose, via various mechanisms such as increased production of advanced glycation end products, activation of protein kinase C, stimulation of the polyol pathway and enhanced reactive oxygen species generation, regulates vascular inflammation, altered gene expression of growth factors and cytokines, and platelet and macrophape activation. thus playing a central role in the development and progression of diabetic vascular complications. This article summarizes the molecular mechanisms of diabetic vascular complications and the potential therapeutic interventions that may prevent these disorders even in the presence of hyperglycemia, control of which is often difficult with current therapeutic options.
引用
收藏
页码:2279 / 2299
页数:21
相关论文
共 276 条
[11]   Oral adsorbent AST-120 ameliorates interstitial fibrosis and transforming growth factor-β1 expression in spontaneously diabetic (OLETF) rats [J].
Aoyama, I ;
Shimokata, K ;
Niwa, T .
AMERICAN JOURNAL OF NEPHROLOGY, 2000, 20 (03) :232-241
[12]  
Arauz-Pacheco Carlos, 1992, Journal of Diabetes and its Complications, V6, P131, DOI 10.1016/1056-8727(92)90024-F
[13]   Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine [J].
Babaei-Jadidi, R ;
Karachalias, N ;
Ahmed, N ;
Battah, S ;
Thornalley, PJ .
DIABETES, 2003, 52 (08) :2110-2120
[14]   Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy [J].
Banba, N ;
Nakamura, T ;
Matsumura, M ;
Kuroda, H ;
Hattori, Y ;
Kasai, K .
KIDNEY INTERNATIONAL, 2000, 58 (02) :684-690
[15]  
Benjamin LE, 1998, DEVELOPMENT, V125, P1591
[16]  
Bierhaus A, 1997, CIRCULATION, V96, P2262
[17]   AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept [J].
Bierhaus, A ;
Hofmann, MA ;
Ziegler, R ;
Nawroth, PP .
CARDIOVASCULAR RESEARCH, 1998, 37 (03) :586-600
[18]   Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial [J].
Boaz, M ;
Smetana, S ;
Weinstein, T ;
Matas, Z ;
Gafter, U ;
Iaina, A ;
Knecht, A ;
Weissgarten, Y ;
Brunner, D ;
Fainaru, M ;
Green, MS .
LANCET, 2000, 356 (9237) :1213-1218
[19]   Increased prevalence of microthromboses in retinal capillaries of diabetic individuals [J].
Boeri, D ;
Maiello, M ;
Lorenzi, M .
DIABETES, 2001, 50 (06) :1432-1439
[20]   Age-dependent activation of PKC isoforms by angiotensin II in the proximal nephron [J].
Boesch, DM ;
Garvin, JL .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2001, 281 (03) :R861-R867